Assertio's revenue declines sharply in Q4 after Rolvedon sell-in
Overview
U.S. pharmaceutical firm's Q4 revenue fell sharply, driven by lower Rolvedon sales after Q3 sell-in
Adjusted loss per share and adjusted EBITDA loss for Q4 were narrower than analysts expected
Company expects 2026 adjusted EBITDA to rise
Outlook
Assertio sees FY2026 net product sales between $110 mln and $125 mln
Company expects FY2026 adjusted EBITDA of $28 mln to $40 mln
Sales of Rolvedon under new label expected to begin in Q2 2026
Result Drivers
ROLVEDON SELL-IN IMPACT - Q4 Rolvedon sales fell sharply due to prior quarter sell-in to support distribution transition, per co
SYMPAZAN GROWTH - Sympazan sales rose on higher volume and favorable payor mix
INDOCIN STABLE - Indocin sales were flat as volume declines from generic competition were offset by higher net pricing
Company press release: ID:nBw9wmXH1a
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue |
| $13.50 mln |
|
Q4 Adjusted EPS | Beat | -$1.06 | -$2.71 (4 Analysts) |
Q4 EPS |
| -$1.86 |
|
Q4 Net Income |
| -$11.90 mln |
|
Q4 Adjusted EBITDA | Beat | -$4.10 mln | -$5.61 mln (3 Analysts) |
Q4 Income From Operations |
| -$11.75 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Assertio Holdings Inc is $40.00, about 246.6% above its March 13 closing price of $11.54
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
